{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T22:48:16Z","timestamp":1773269296094,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.pupt.2022.102182","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T13:31:21Z","timestamp":1669728681000},"page":"102182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Efficacy and safety of non-prostanoid prostacyclin receptor agonist for pulmonary hypertension: A meta-analysis"],"prefix":"10.1016","volume":"78","author":[{"given":"Pengwei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongli","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honglei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujuan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianlian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yizhong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijian","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.pupt.2022.102182_bib1","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1161\/CIRCRESAHA.121.319815","article-title":"Endothelial senescence: a new age in pulmonary hypertension","volume":"130","author":"Culley","year":"2022","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.pupt.2022.102182_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.pupt.2022.102182_bib3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-2600(15)00543-3","article-title":"A global view of pulmonary hypertension","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.pupt.2022.102182_bib4","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1161\/HYPERTENSIONAHA.120.14525","article-title":"Innovative anti-inflammatory and pro-resolving strategies for pulmonary hypertension: high blood pressure research council of Australia award 2019","volume":"78","author":"Scott","year":"2021","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.pupt.2022.102182_bib5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.33963\/KP.15928","article-title":"Recent advances in the pharmacotherapy of pulmonary hypertension: practical considerations","volume":"79","author":"Lareo","year":"2021","journal-title":"Kardiol. Pol."},{"issue":"1","key":"10.1016\/j.pupt.2022.102182_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.pupt.2022.102182_bib7","doi-asserted-by":"crossref","first-page":"ITC49","DOI":"10.7326\/AITC202104200","article-title":"Pulmonary hypertension","volume":"174","author":"Poch","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pupt.2022.102182_bib8","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2147\/IJGM.S295463","article-title":"Treating inflammation associated with pulmonary hypertension: an overview of the literature","volume":"15","author":"Yoo","year":"2022","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.pupt.2022.102182_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.819145","article-title":"Dysregulated immunity in pulmonary hypertension: from companion to composer","volume":"13","author":"Funk-Hilsdorf","year":"2022","journal-title":"Front. Physiol."},{"issue":"4","key":"10.1016\/j.pupt.2022.102182_bib10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/sj.bjp.0707413","article-title":"New insights into human prostacyclin receptor structure and function through natural and synthetic mutations of transmembrane charged residues","volume":"152","author":"Stitham","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pupt.2022.102182_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1877-1173(09)89006-6","article-title":"The human prostacyclin receptor from structure function to disease","volume":"89","author":"Martin","year":"2009","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"18","key":"10.1016\/j.pupt.2022.102182_bib12","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.1021\/acs.jmedchem.5b00698","article-title":"Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"58","author":"Asaki","year":"2015","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.pupt.2022.102182_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020922814","article-title":"Safety, tolerability, and pharmacokinetics of the selective prostacyclin receptor agonist ralinepag in single and multiple dosing studies of an immediate-release oral formulation in healthy volunteers","volume":"10","author":"Grundy","year":"2020","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.pupt.2022.102182_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.prostaglandins.2015.04.007","article-title":"The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: role of membrane versus nuclear receptors","volume":"120","author":"Clapp","year":"2015","journal-title":"Prostag. Other Lipid Mediat."},{"key":"10.1016\/j.pupt.2022.102182_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102100","article-title":"Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: a meta-analysis","volume":"72","author":"Chen","year":"2022","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"14","key":"10.1016\/j.pupt.2022.102182_bib16","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacc.2021.07.057","article-title":"Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension","volume":"78","author":"Chin","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.pupt.2022.102182_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01694-2021","article-title":"Selexipag for the treatment of chronic thromboembolic pulmonary hypertension","volume":"60","author":"Ogo","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2022.102182_bib18","author":"Pfister"},{"issue":"4","key":"10.1016\/j.pupt.2022.102182_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01030-2019","article-title":"Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial","volume":"54","author":"Torres","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.pupt.2022.102182_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"key":"10.1016\/j.pupt.2022.102182_bib21","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3","year":"2022"},{"key":"10.1016\/j.pupt.2022.102182_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.pupt.2022.102182_bib23","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"issue":"4","key":"10.1016\/j.pupt.2022.102182_bib24","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"26","key":"10.1016\/j.pupt.2022.102182_bib25","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.pupt.2022.102182_bib26","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1253\/circj.CJ-20-0438","article-title":"Selexipag for chronic thromboembolic pulmonary hypertension in Japanese patients-a double-blind, randomized, placebo-controlled, multicenter phase II study","volume":"84","author":"Tanabe","year":"2020","journal-title":"Circ. J."},{"key":"10.1016\/j.pupt.2022.102182_bib27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijcard.2021.04.003","article-title":"Risk stratification in patients with residual pulmonary hypertension after pulmonary endarterectomy","volume":"334","author":"Ghio","year":"2021","journal-title":"Int. J. Cardiol."},{"issue":"5","key":"10.1016\/j.pupt.2022.102182_bib28","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1164\/rccm.201203-0480OC","article-title":"The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension","volume":"186","author":"Mathai","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.pupt.2022.102182_bib29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/CIRCULATIONAHA.112.105890","article-title":"Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials","volume":"126","author":"Gabler","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pupt.2022.102182_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.vph.2005.03.003","article-title":"The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect","volume":"43","author":"Frost","year":"2005","journal-title":"Vasc. Pharmacol."},{"issue":"5","key":"10.1016\/j.pupt.2022.102182_bib31","article-title":"Prostacyclin for pulmonary arterial hypertension","volume":"5","author":"Barnes","year":"2019","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553922000736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553922000736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:31:12Z","timestamp":1761082272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553922000736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":31,"alternative-id":["S1094553922000736"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2022.102182","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of non-prostanoid prostacyclin receptor agonist for pulmonary hypertension: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2022.102182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102182"}}